Insilico Medicine explores use of 3CL protease inhibitor for COVID-19 treatment

Insilico Medicine, a China & US-based clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery c...

May 25, 2022 | Wednesday | News
Japanese firms initiate joint research on next-gen IT drug discovery technology

Japan-based Fujitsu and RIKEN have launched a joint research project on next-generation IT drug discovery technology uti...

May 17, 2022 | Tuesday | News
University of Tokyo, Astellas further advance development of innovative medicines

The University of Tokyo and Astellas Pharma Inc., in Japan, have entered the second phase of their collaboration for co-...

April 27, 2022 | Wednesday | News
FDA grants Fast Track designation for Paradigm Biopharmaceuticals Phase III Osteoarthritis Program

Australia's Paradigm Biopharmaceuticals, a clinical stage biopharmaceutical company focused on repurposing existing...

April 14, 2022 | Thursday | News
TauRx's late-stage clinical trial reaches new milestone

TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer's Disease (AD) research, has announced that the last p...

April 14, 2022 | Thursday | News
Otsuka and Akebia seek USFDA approval for renal anemia drug

Otsuka Pharmaceutical has announced that its collaborator Akebia Therapeutics, Inc. (Akebia) has submitted a New Drug Ap...

April 1, 2022 | Friday | News
Insilico Medicine partners with EQRx for AI-driven drug discovery

Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, has entered i...

March 25, 2022 | Friday | News
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments

Biogen Inc. and Eisai Co., Ltd. announced that the companies have amended their existing collaboration agreement on aduc...

March 21, 2022 | Monday | News
RedHill inks deal worth $6M with Kukbo for COVID-19 drug in South Korea

RedHill Biopharma has entered into an exclusive license agreement with Kukbo Co., a South Korean corporation, for o...

March 16, 2022 | Wednesday | News
Astellas’ menopause drug fails in Asia trial

Japan-based Astellas Pharma Inc. has announced topline results from the ongoing Phase 3 MOONLIGHT 1 clinical trial inves...

March 16, 2022 | Wednesday | News
China approves SCG's T Cell Therapy IND to treat Hepatitis B virus

Singapore-based SCG Cell Therapy Pte Ltd, a leading biotechnology company,  announced that the China National Medic...

March 14, 2022 | Monday | News
China's Gan & Lee Pharma begins first-in-human trial for diabetes drug

Chinese firm Gan & Lee Pharmaceuticals has announced that the first subject has been dosed in our Phase I, double-bl...

March 11, 2022 | Friday | News
Dr Andreas Amrein joins Advanced Clinical to lead global development and expansion in APAC

Advanced Clinical, a clinical development and strategic resourcing organization committed to providing a better clinical...

March 10, 2022 | Thursday | News
China approves phase II trial of Akeso's cancer drug

Akeso, Inc., a biopharmaceutical company dedicated to the development of innovative antibody drugs, has announced that t...

March 8, 2022 | Tuesday | News
I-Mab receives FDA orphan drug designation for cancer drug

China based I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializa...

March 4, 2022 | Friday | News
China-based startup InxMed raises $50 M in Series B Financing

InxMed Co., Ltd, a clinical-stage biotechnology startup based in China, has announced that it had completed $5...

March 4, 2022 | Friday | News
China's Adagene partners with French firm Sanofi for Immuno-Oncology

China's Adagene,  a company transforming the discovery and development of antibody-based therapies, has announced a...

March 3, 2022 | Thursday | News
China approves Phase II clinical trial of InnoCare's cancer drug

InnoCare Pharma, a leading biopharmaceutical company, has announced the Investigational New Drug (IND) approval of its B...

March 3, 2022 | Thursday | News